{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-126349","form_type":"8-K","ticker":"RGEN","cik":"0000730272","company_name":"REPLIGEN CORP","filed_at":"2024-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.855769+00:00","generated_at":"2026-06-03T03:30:44.708181+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Repligen Q1 revenue falls 17% to $151M; GAAP EPS $0.04, adjusted EPS $0.28","bullets":["Q1 revenue $151.3M, down from $182.7M YoY; GAAP net income $2.1M ($0.04 diluted EPS) vs $28.8M ($0.51).","Adjusted net income $15.8M ($0.28 diluted EPS) vs $36.3M ($0.64); adjusted gross margin 48.6% vs 55.2%.","New modalities revenue up 16% YoY; Filtration (non-COVID) up 12% YoY; book-to-bill 0.99 (Q1), 1.03 (nine-month).","FY2024 guidance reaffirmed: revenue $620M-$650M, adjusted EPS $1.42-$1.49, adjusted op margin 13%-14%.","Cash and investments $780.6M as of March 31, 2024; Metenova added over $5M revenue in Q1."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-126349","json":"https://secwatch.observer/filing/0001193125-24-126349.json","markdown":"https://secwatch.observer/filing/0001193125-24-126349.md","text":"https://secwatch.observer/filing/0001193125-24-126349.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/730272/000119312524126349/0001193125-24-126349-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/730272/000119312524126349/d780642d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T03:30:44.708181+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1f6a05488a39d6f57365c7139e096a21e8a2cb77","claim":"REPLIGEN CORP reported first quarter of 2024, covering the three-month period ended March 31, 2024 results: revenue $151.3 million, net income $2.1 million, EPS $0.04. Guidance reaffirmed.","evidence_excerpt":"Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports First Quarter 2024 Financial Results • Reports first quarter revenue of $151 million • Increased new modalities revenue by 16% year-over-year • Increased Filtration (non-COVID) revenue by 12% year-over-year • Achieved a nine-month book-to-bill ratio of 1.03","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/730272/000119312524126349/0001193125-24-126349-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter of 2024, covering the three-month period ended March 31, 2024"},{"label":"Revenue","value":"$151.3 million"},{"label":"Net income","value":"$2.1 million"},{"label":"EPS","value":"$0.04"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}